Olema Pharmaceuticals, Inc. — Fiscal 2020 Form 10-K Summary
Business context and reporting period
Olema Pharmaceuticals is a clinical-stage biopharmaceutical company focused on targeted therapies for women’s cancers. Its lead and only product candidate, OP-1250, is an oral complete estrogen receptor antagonist and selective estrogen receptor degrader for ER-positive/HER2-negative breast cancer. The filing covers the fiscal year ended December 31, 2020 and was filed March 17, 2021.
In August 2020, Olema initiated a Phase 1/2 trial of OP-1250 in recurrent, locally advanced or metastatic ER-positive/HER2-negative breast cancer. The company expected to report initial Phase 1 data in the second half of 2021. OP-1250 had not been approved for commercial sale, and the company had no product revenue.
Financial performance, liquidity and capital structure
| Metric | 2020 | 2019 | Change |
|---|---|---|---|
| Revenue | $0 | $0 | No product revenue |
| Research and development expense | $13.7 million | $3.9 million | +$9.8 million |
| General and administrative expense | $7.8 million | $0.4 million | +$7.4 million |
| Total operating expenses | $21.5 million | $4.3 million | +$17.2 million |
| Loss from operations | $(21.5) million | $(4.3) million | Higher loss |
| Net loss | $(22.1) million | $(4.3) million | Higher loss |
| Net loss attributable to common stockholders | $(24.0) million | $(4.3) million | Includes $1.9 million preferred-stock repurchase impact |
| Basic and diluted loss per share | $(3.42) | $(1.66) | More shares and higher loss |
| Net cash used in operating activities | $(19.9) million | $(3.1) million | Greater cash burn |
| Cash and cash equivalents at year-end | $338.5 million | $0.1 million | Substantial increase |
| Debt outstanding at year-end | None | None reported | 2020 convertible notes were converted |
Operating and net margins are not meaningful because the company generated no revenue. The accumulated deficit was $33.1 million at December 31, 2020. Management believed existing cash would fund planned operating expenses and capital expenditures through the end of 2022, although substantial additional financing would be required thereafter to continue development.
Financing cash inflows totaled $358.4 million in 2020, including approximately $220.6 million of net IPO proceeds, $85.8 million of net Series C preferred-stock proceeds, $50.6 million of net Series B preferred-stock proceeds and $3.0 million of convertible-note proceeds, partly offset by a $2.3 million preferred-stock repurchase. The IPO issued 12.65 million shares at $19.00 per share and closed November 23, 2020.
Material changes versus the prior comparable period
- R&D spending increased approximately 250%, primarily reflecting advancement of OP-1250 into clinical development, manufacturing costs, additional discovery work, higher personnel costs and $2.0 million of additional R&D stock-based compensation.
- G&A expense increased substantially because of expanded executive staffing, IPO and public-company costs, outside consultants and $1.1 million of additional G&A stock-based compensation.
- Net cash used in operations increased from $3.1 million to $19.9 million as development activity and staffing expanded.
- Cash increased from $68 thousand to $338.5 million following the IPO and private financing transactions.
- All outstanding convertible preferred stock converted into common stock upon the IPO; year-end common shares outstanding were 39.3 million.
- The company entered clinical collaborations with Novartis for combinations with ribociclib and alpelisib and with Pfizer for a combination with palbociclib. Novartis agreed to supply study drugs and reimburse a capped majority of specified outside costs; Pfizer agreed to provide palbociclib at no cost.
- Previously identified material weaknesses in internal control over financial reporting were reported as remediated as of December 31, 2020. The company remained exempt from auditor attestation under its emerging-growth-company status.
Guidance, outlook, risks and unusual items
Management expected continued and increasing operating losses for the foreseeable future as OP-1250 advances through clinical trials and regulatory development. The company did not provide product-revenue or profitability guidance. It expected to require substantial additional capital after its projected cash runway through year-end 2022.
- OP-1250 is the company’s only product candidate and remains in early-stage clinical development. Nonclinical tumor-shrinkage and brain-penetration results have not established clinical efficacy or safety.
- Clinical trials may be delayed, fail to demonstrate safety or efficacy, or be placed on hold. COVID-19 caused some delays in trial setup and site initiation and could affect enrollment, CROs, manufacturing, regulators and data quality.
- The company relies on third-party CROs, clinical investigators and contract manufacturers. It had no manufacturing facilities, no long-term OP-1250 supply agreements and some single-source raw-material dependencies.
- Regulatory approval is uncertain and may require additional studies, restrictive labeling, post-approval commitments or a risk evaluation and mitigation strategy.
- Competition includes approved endocrine therapies and multiple oral CERAN/SERD candidates under development by larger or better-funded companies.
- Additional equity or debt financing may dilute shareholders, impose restrictive covenants or require the company to surrender rights to OP-1250 or future programs.
- The financial statements were prepared on a going-concern basis; management stated that accumulated losses and negative operating cash flows raised substantial doubt about long-term ability to continue without additional funding.
- Unusual 2020 items included a $653 thousand interest expense, primarily related to the beneficial conversion feature of the 2020 convertible notes, a $1.9 million charge related to repurchase and retirement of Series A and A-1 preferred stock, and $3.1 million of stock-based compensation.
- Contractual operating-lease obligations totaled approximately $6.8 million as of December 31, 2020. No material litigation or off-balance-sheet arrangements were reported.
- After year-end, the compensation committee approved a one-time tax-adjusted reimbursement payment of $109,936 to the Chief Development Officer related to repayment of a company loan.
Most important facts for investors to verify
- Confirm the current clinical status, enrollment, safety, pharmacokinetic data and efficacy results for the OP-1250-001 trial and any combination studies.
- Assess whether the reported $338.5 million cash balance and projected runway remain adequate after subsequent operating expenditures and financings.
- Track quarterly R&D spending, operating cash burn, stock-based compensation and the timing and terms of any future capital raises.
- Review regulatory interactions, potential expedited designations, clinical holds and the requirements for any future NDA submission.
- Evaluate OP-1250’s intellectual-property coverage, pending foreign applications, patent-term prospects and potential third-party infringement claims.
- Monitor manufacturing capacity, supply redundancy, CMO performance and the effect of COVID-19 or other disruptions on trial execution.
- Review dilution from outstanding options, restricted stock, the employee stock purchase plan and future equity financings.